Two-year results of the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr) will allow physicians and patients to have more educated conversations about procedures for stress urinary incontinence and what can be expected in terms of efficacy and complications, according to the investigators of that prospective, randomized, National Institute of Diabetes and Digestive and Kidney Diseases-supported trial.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.